Phase I testing of SIM0609 in adults with advanced or metastatic solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, multicenter Phase I trial gives escalating doses of SIM0609 to adults with histologically confirmed locally advanced or metastatic solid tumors to define safety, tolerability, and pharmacokinetics and to look for early signs of antitumor activity. After dose escalation, predefined dose-expansion cohorts will enroll patients with colorectal cancer, gastric/gastroesophageal junction cancer, pancreatic ductal adenocarcinoma, and other selected solid tumors. Key eligibility includes measurable disease, ECOG 0–1, adequate organ and marrow function, and available tumor tissue for biomarker analysis. Primary endpoints focus on safety and tolerability with secondary endpoints including pharmacokinetics and preliminary tumor response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntary participation and signature of informed consent form;
2. At least 18 years old, male or female;
3. Participants with histologically and/or cytologically confirmed locally advanced/metastatic solid tumors;
4. Participants should have at least one evaluable or measurable tumor lesion;
5. Participants have failed the standard of therapy in the locally advanced/metastatic setting;
6. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1;
7. Expected survival ≥12 weeks;
8. Adequate organ and bone marrow function;
9. Availability of archival formalin-fixed, paraffin-embedded (FFPE) tumor tissue, or fresh biopsies within 28 days before first administration, is mandatory

Exclusion Criteria:

1. Active second primary malignancies within the previous 2 years except for localized cancers that are considered to have been cured and in the opinion of the Investigator present a low risk for recurrence;
2. Symptomatic central nervous system (CNS) metastases or CNS metastases requiring CNS-directed local therapy or corticosteroid treatment that occurred within 2 weeks prior to the first administration of the investigational treatment;
3. Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging screening;
4. Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study ;
5. Any active infections requiring systemic therapy within 2 weeks prior to the initiation of the study treatment;
6. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring drainage or medical intervention within 4 weeks before the first dose of study treatment;
7. Not recovered from previous anticancer therapy-induced AEs(Adverse Events);
8. Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of first dose of study treatment;
9. Received prior therapies within the following time frames prior to the first dose of study treatment:

   1. Previous cytotoxic therapy, anticancer targeted small molecules within 2 weeks.
   2. Anti-cancer antibody, immune checkpoint inhibitor or ADC within 5 half-lives or 4 weeks (whichever is shorter).
   3. Chinese medicines/herbal preparations with anticancer indication taken within 2 weeks.
   4. Radiation therapy within 4 weeks.
10. Prior exposure to topoisomerase I inhibitor (TOP1i)-based antibody drug conjugate (ADC) therapies or CDH17-targeted ADC therapies.
11. Use of any live vaccine therapy within 4 weeks prior to the first dose of study treatment.
12. Administration of below medications ≤14 days prior to the first dose of study treatment.

    1. Strong or moderate CYP3A4 inducers/inhibitors;
    2. Drugs with known risk of Torsades de Pointes(TdP);
    3. Drugs that may prolong the QT interval;
13. Major surgery within 2 weeks of receiving the first dose of study treatment;
14. Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome ;
15. Active or chronic hepatitis B or hepatitis C infection;
16. Participants with clinically significant cardiovascular diseases;
17. History of allogeneic organ transplantation or graft-versus-host disease;
18. History of hypersensitivity to active or inactive excipients of SIM0609 or drugs with a similar chemical structure or class to SIM0609;
19. Pregnant or nursing (lactating) women;
20. Male participants with female partners of reproductive potential, unless they are using highly effective contraceptive methods from signing of informed consent to 180 days after the last dose of study treatment;
21. Presence of any other condition that may increase the risk associate with study participant or may interfere with the interpretation of study results, and, in the opinion of the Investigator, would make the participant inappropriate for entry into the study.

Where it's running

• Beijing Cancer Hospital
  Beijing, China Recruiting
• Jiangsu Province Hospital
  Nanjing, China Not yet recruiting
• Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, China Not yet recruiting
• Zhongshan Hospital，Fudan University
  Shanghai, China Not yet recruiting
• Tianjin Cancer Hospital
  Tianjin, China Not yet recruiting
• Hubei Cancer Hospital
  Wuhan, China Not yet recruiting

Study contacts

• Study coordinator: Jinxiu Zhang
• Email: zhangjinxiu@zaiming.com
• Phone: 86-010-65212241

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SIM0613 in people with advanced solid tumors

  A first-in-human, multicenter study testing SIM0613 to see if it is safe and tolerable and whether it has any effect in adults with advanced solid cancers.

  Recruiting Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Tianjin, Tianjin Municipality · NCT07618260

• Testing how well different doses of BI 3819026 can be tolerated alone and with ezabenlimab in advanced cancer

  This study tests whether varying doses of BI 3819026 can be tolerated by adults with advanced solid cancers, both by itself and in combination with ezabenlimab.

  Recruiting at 8 sites Phase 1 Boehringer Ingelheim · New Haven, Connecticut and 8 other locations · NCT07607678

• Personalized KXV01 TCR Lentinvivo Injection for Advanced Solid Tumors

  A first-in-human, single-arm study tests a KXV01 TCR lentiviral treatment given in vivo to see if it is safe and tolerable for adults with advanced solid cancers that have exhausted standard therapies.

  Recruiting Phase 1 TCRx Therapeutics Co.Ltd · Hefei, Anhui · NCT07196579

• APX-343A alone or with pembrolizumab for advanced solid tumors

  This Phase 1 trial will test whether APX-343A by itself or combined with the immunotherapy pembrolizumab is safe and shows early benefit in adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 Aptabio Therapeutics, Inc. · Seongnam and 2 other locations · NCT07123415

• MHB046C injection for adults with advanced solid tumors

  This study will test whether MHB046C injections are safe and might shrink or control advanced solid tumors in adults who have no standard treatment options.

  Recruiting Phase 1/2 Minghui Pharmaceutical (Hangzhou) Ltd · Guangzhou, Guangdong · NCT06985355

• SYN818 for advanced or metastatic solid tumors

  This Phase 1 study will test oral SYN818 in adults with advanced or metastatic solid tumors, including breast, ovarian, and prostate cancers, whose standard treatments have been exhausted.

  Recruiting at 2 sites Phase 1 Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Zhengzhou, Henan and 1 other locations · NCT06666270

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.